About Beta-1 adrenergic receptor
Beta-1 adrenergic receptor (ADRB1) is a protein
from Homo sapiens identified by UniProt accession
P08588, 477 residues long.
MolForge cross-references it against 0 known binders and
520 disease associations.
Target properties
| Protein name | Beta-1 adrenergic receptor |
| UniProt accession | P08588 |
| Gene | ADRB1 |
| Organism | Homo sapiens |
| Length | 477 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (520)
Diseases linked to this target (Open Targets).
- hypertension · score 0.72
- cardiovascular disease · score 0.70
- myocardial infarction · score 0.61
- essential hypertension · score 0.61
- heart failure · score 0.61
- open-angle glaucoma · score 0.61
- migraine disorder · score 0.61
- glaucoma · score 0.61
- angina pectoris · score 0.61
- atrial fibrillation · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P08588-F1 | alphafold | PREDICTED | 75.33 | — |
Amino-acid sequence (477 residues)
MGAGVLVLGA SEPGNLSSAA PLPDGAATAA RLLVPASPPA SLLPPASESP EPLSQQWTAG MGLLMALIVL LIVAGNVLVI VAIAKTPRLQ TLTNLFIMSL ASADLVMGLL VVPFGATIVV WGRWEYGSFF CELWTSVDVL CVTASIETLC VIALDRYLAI TSPFRYQSLL TRARARGLVC TVWAISALVS FLPILMHWWR AESDEARRCY NDPKCCDFVT NRAYAIASSV VSFYVPLCIM AFVYLRVFRE AQKQVKKIDS CERRFLGGPA RPPSPSPSPV PAPAPPPGPP RPAAAAATAP LANGRAGKRR PSRLVALREQ KALKTLGIIM GVFTLCWLPF FLANVVKAFH RELVPDRLFV FFNWLGYANS AFNPIIYCRS PDFRKAFQGL LCCARRAARR RHATHGDRPR ASGCLARPGP PPSPGAASDD DDDDVVGATP PARLLEPWAG CNGGAAADSD SSLDEPCRPG FASESKV
Explore Beta-1 adrenergic receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets